Guidant Holds To 2005 Drug-Eluting Stent E.T.A. Despite Trial Delay
This article was originally published in The Gray Sheet
Executive Summary
The start of Guidant's SPIRIT FIRST dose-selection clinical trial for the everolimus-eluting Vision stent will be delayed three to six months due to foreign-body responses detected in pre-clinical studies